WO2019170912A1 - Compositions biorésorbables à libération contrôlée comprenant des molécules modulant sting - Google Patents

Compositions biorésorbables à libération contrôlée comprenant des molécules modulant sting Download PDF

Info

Publication number
WO2019170912A1
WO2019170912A1 PCT/EP2019/056006 EP2019056006W WO2019170912A1 WO 2019170912 A1 WO2019170912 A1 WO 2019170912A1 EP 2019056006 W EP2019056006 W EP 2019056006W WO 2019170912 A1 WO2019170912 A1 WO 2019170912A1
Authority
WO
WIPO (PCT)
Prior art keywords
sting
bioresorbable
hydratable
release
pharmaceutical composition
Prior art date
Application number
PCT/EP2019/056006
Other languages
English (en)
Inventor
Stefan GRUDÉN
Niklas AXÉN
Martin Johansson
Original Assignee
Lidds Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidds Ab filed Critical Lidds Ab
Publication of WO2019170912A1 publication Critical patent/WO2019170912A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Definitions

  • the present invention relates to novel pharmaceutical compositions comprising a non- densified and porous or highly densified and non-porous, and at least partly hydrated hydrating ceramic, such as calcium sulfate, for controlled-release of an agent that can modulate the STING pathway, preferably activate, for therapeutically, prophylactically, and/or diagnostically active purposes.
  • a non- densified and porous or highly densified and non-porous and at least partly hydrated hydrating ceramic, such as calcium sulfate, for controlled-release of an agent that can modulate the STING pathway, preferably activate, for therapeutically, prophylactically, and/or diagnostically active purposes.
  • the STING modulator may be a small molecule, a polypeptide, or a nucleic acid derivative, such as a cyclic dinucleotide (CDN).
  • CDN cyclic dinucleotide
  • compositions of the present invention are useful for targeted and controlled local prolonged release of STING modulators.
  • Stimulator of interferon genes is a transmembrane protein that is expressed in various endothelial, epithelial and haematopoietic cells.
  • STING an endoplasmic reticulum-resident protein, upon binding of cGAMP or other cyclic dinucleotide (CDN) structures, phosphorylates the adaptor protein TBK1 , which, in turn, phosphorylates IRF-3 and initiates the transcription of a number of interferon stimulated genes, including type I interferons and other co-regulated host defense pathways and cytokines.
  • STING can be activated by bacterial and viral DNA as well as self-DNA. The ability of STING activation to promote an immune response to tumors can lead to a T cell response which is required for antitumor effect of checkpoint inhibitor-based immunotherapies. As such STING modulation is a promising new treatment modality for different cancers.
  • STING modulators in particular STING activators or agonists
  • severe adverse events e.g. cytokine release
  • STING agonists might be required to be given at multiple time points over the treatment course in order to achieve desired effects. This would require multiple local, intralesional injections which might be costly, time consuming and painful to the receiving patient.
  • drug profile achieved with multiple injections could be less than optimal. Therefore, new release formulations of STING modulating molecules, agents or ligands are warranted.
  • the present invention relates to drug delivery systems composed of bioresorbable inorganic and hydratable carriers combined with STING modulating molecules, especially cyclic dinucleotides that are STING modulating molecules, for prolonged delivery of these large molecules in a human body.
  • STING modulating molecules especially cyclic dinucleotides that are STING modulating molecules
  • the bioresorbable ceramics have many favorable properties for pharmaceutical formulations in controlled release applications as compared to polymers, such as biocompatibility and biodegradability.
  • the bioresorbable ceramics are non- toxic and are based on molecules which normally is present in the living tissues of mammals. Calcium sulphate is particularly attractive since it is a resorbable and biocompatible material, i.e. it disappears over time.
  • One aspect of the present invention relates to encapsulation of STING modulating molecules, such as cyclic dinucleotides (CDN) in depots consisting of a matrix of partly hydrated or fully hydrated, porous or dense calcium sulfate.
  • STING modulating molecules such as cyclic dinucleotides (CDN)
  • CDN cyclic dinucleotides
  • Such encapsulated STING modulating molecules may thereafter be slowly released from the depot in a biological environment of living cells, such as a human or animal body, and maintaining the therapeutically, prophylactically, and/or diagnostically properties and effects of the STING modulating molecules on said cells.
  • the STING modulating molecules, such as cyclic dinucleotides will thus act as an active pharmaceutical ingredient (API) and the matrix of partly hydrated or fully hydrated, porous or dense calcium sulfate will act as a pharmaceutical excipient.
  • API active pharmaceutical ingredient
  • Embodiment 1 A controlled-release pharmaceutical composition comprising one or more hydratable and bioresorbable ceramics or hydrating inorganic compound and one or more therapeutically, prophylactically, and/or diagnostically active STING modulating molecules.
  • Embodiment 2. A controlled-release pharmaceutical composition, wherein the hydratable and bioresorbable ceramics is selected from the group consisting of non- hydrated, partly hydrated and/or fully hydrated calcium sulfate.
  • Embodiment 3 A controlled-release pharmaceutical composition according to the present invention, wherein the hydratable and bioresorbable ceramic has been fully or partly compressed to a high density.
  • Embodiment 4 A controlled-release pharmaceutical composition according to the present invention, wherein the hydratable and bioresorbable ceramic has been fully or partly compressed in an isostatic press.
  • Embodiment 5 A controlled-release pharmaceutical composition according to the present invention, comprising a mixture of non-compressed and compressed ceramic material, such as calcium sulphate.
  • Embodiment 6 A controlled-release pharmaceutical composition according to the present invention, wherein the STING modulating agent is selected from the group consisting of one or more, nucleic acids and/or small molecules.
  • Embodiment 7 A controlled-release pharmaceutical composition according to the present invention, wherein the STING modulating molecule is a cyclic dinucleotide.
  • Embodiment 8 A controlled-release pharmaceutical composition according to the present invention, wherein the STING modulating molecule wherein the cyclic dinucleotide is chosen from ADU-S100 (MIW815), MK-1454, cyclic diguanylate monophosphate (c-di-GMP), cyclic [G(2',5')pA(3',5')p] (cGAMP) and ML RR-S2 CDA.
  • the STING modulating molecule wherein the cyclic dinucleotide is chosen from ADU-S100 (MIW815), MK-1454, cyclic diguanylate monophosphate (c-di-GMP), cyclic [G(2',5')pA(3',5')p] (cGAMP) and ML RR-S2 CDA.
  • Embodiment 9 A controlled-release pharmaceutical composition according to the present invention for use in the treatment of cancer.
  • Embodiment 10 A controlled-release pharmaceutical composition according to the present invention, for injection into a solid cancer tumor - i.e. intra-tumoral injection.
  • Embodiment 1 A method of treating a human being afflicted with a cancer tumor, comprising administering to a tumor site one or more hydratable and bioresorbable ceramics or hydrating inorganic compounds and one or more therapeutically, prophylactically and/or diagnostically active STING modulating molecules.
  • Embodiment 12 A method according to the present invention, wherein the hydratable and bioresorbable ceramics is selected from the group consisting of non-hydrated, partly hydrated and/or fully hydrated calcium sulfate.
  • Embodiment 13 A method according to the present invention, wherein the hydratable and bioresorbable ceramic has been compressed to a high density.
  • Embodiment 14 A method according to the present invention, wherein the hydratable and bioresorbable ceramic has been compressed in an isostatic press.
  • Embodiment 15 A method according to the present invention, comprising a mixture of non-compressed and compressed ceramic material.
  • Embodiment 16 A method according to the present invention, wherein the STING modulating molecule is a cyclic dinucleotide.
  • Embodiment 17 A method according to the present invention, wherein the cyclic dinucleotide is a chosen from ADU-S100 (MIW815), MK-1454, cyclic diguanylate monophosphate (c-di-GMP), cyclic [G(2',5')pA(3',5')p] (cGAMP) and ML RR-S2 CDA.
  • the cyclic dinucleotide is a chosen from ADU-S100 (MIW815), MK-1454, cyclic diguanylate monophosphate (c-di-GMP), cyclic [G(2',5')pA(3',5')p] (cGAMP) and ML RR-S2 CDA.
  • Figure 1 shows the tumor growth of syngeneic tumors following intratumoral adminsitration of a controlled release formulation of a STING agonist according to Example 3.
  • Figure 2 shows the survival of animals treated in Example 3.
  • Figure 3 shows the tumor volume in relation to days elapsed for the respective groups in Example 4, where figure 3a shows group 1 , figure 3b shows group 2, figure 3c shows group 3, figure 3d shows group 4 and figure 3e shows group 5, respectively.
  • Figure 4 shows the terminal tumor weight, as recorded following excision on the final day of the study in Example 4.
  • bioresorbable (or biodegradable) polymers are polylactic acids and polylactic-co-glycolide-acids.
  • Various calcium-salt based ceramics e.g. calcium phosphate or calcium sulphate systems, or hydroxylapatite, have been described in the form of beads, granules, scaffolds, or moldable pastes, to carry and release drugs. These ceramics are often referred to as hydratable or hydrating ceramics due to their ability to react chemically with water to form solid hydrates. See e.g. Royer US
  • W02005039537 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising a bioresorbable hydratable ceramic, sorbed aqueous medium, and an active substance.
  • STING modulators in particular, STING activators or agonists
  • severe adverse events e.g. cytokine release
  • STING agonists should be given locally, intratumorally when treating cancers, to avoid systemic side-effects.
  • STING agonists might be required to be given at multiple time points over the treatment in order to achieve desired effects. This would require multiple local, intralesional injections which might be costly, time consuming and painful to the receiving patient.
  • the drug profile achieved with multiple injections could be less than optimal.
  • a STING modulating agent for example an agonist, could be formulated in a drug delivery system that allows for a local administration leading to a controlled release of the active agent over an extended time.
  • Immunotherapy is the treatment of a disease by inducing, enhancing, or suppressing an immune response. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppressive immunotherapies.
  • Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.
  • different encapsulating techniques have been investigated. These formulations or
  • complexations can e.g. involve formation of nanoparticles, micelles, or lipophilic cation complexes.
  • complexations can e.g. involve formation of nanoparticles, micelles, or lipophilic cation complexes.
  • the bioresorbable ceramics have many favorable properties for pharmaceutical formulations in controlled release applications as compared to polymers, such as biocompatibility and biodegradability.
  • the bioresorbable ceramics are non- toxic and are based on molecules which normally is present in the living tissues of mammals. Calcium sulphate is particularly attractive since it is a resorbable and biocompatible material, i.e. it disappears over time.
  • One aspect of the present invention relates to encapsulation of STING modulating molecules, such as cyclic dinucleotides (CDN) in depots consisting of a matrix of partly hydrated or fully hydrated, porous or dense calcium sulfate.
  • STING modulating molecules such as cyclic dinucleotides (CDN)
  • CDN cyclic dinucleotides
  • Such encapsulated STING modulating molecules may thereafter be slowly released from the depot in a biological environment of living cells, such as a human or animal body, and maintaining the therapeutically, prophylactically, and/or diagnostically properties and effects of the STING modulating molecules on said cells.
  • the STING modulating molecules, such as cyclic dinucleotides will thus act as an active pharmaceutical ingredient (API) and the matrix of partly hydrated or fully hydrated, porous or dense calcium sulfate will act as a pharmaceutical excipient.
  • API active pharmaceutical ingredient
  • the present invention relates to the ability to manufacture a homogeneous dry powder which contains STING modulating molecules, such as cyclic dinucleotides (CDN) that can be long-term stored at room temperature.
  • STING modulating molecules such as cyclic dinucleotides (CDN)
  • CDN cyclic dinucleotides
  • the STING modulating molecules used in the present invention, may for example be embedded into the calcium sulfate matrix by mixing the calcium sulfate powder and the STING modulating molecules and thereafter make the calcium sulfate react with water, i.e. hydrate, to a solid form.
  • This solid form is used as a drug depot.
  • the drug depot dissolves slowly in a water-based environment such as a human or animal body or in a cell medium and is thus suitable for immunotherapy and the like.
  • the STING modulating molecules / active pharmaceutical ingredient (API) may be loaded onto the calcium sulphate matrix, i.e. calcium sulphate hemihydrate, in different ways.
  • the calcium sulphate hemihydrate can for example be mixed with the STING modulating molecules creating a STING modulating molecule-loaded binary mixture. This may be performed by dry mixing. This may also be performed by dissolving the STING modulating molecules in a solvent to which the calcium sulphate is inert (such as an alcohol, preferably 2-propanol). This leads to a slurry of calcium sulphate powder in a solute of STING modulating molecules and solvent. By evaporating the solvent while agitating the slurry a dry powder of STING modulating molecules and calcium sulphate is formed.
  • the loading of the STING modulating molecules can further be done simultaneously in the recrystallization process to calcium sulphate dihydrate using an aqueous solution/dispersion of the STING modulating molecules as the calcium sulphate hemihydrate is converted into other forms of calcium sulphate, such as recrystallized into calcium sulphate dihydrate.
  • the STING modulating molecules -loaded calcium sulphate dihydrates in such a formulation may have different physical properties and release rates / release profiles depending on how the precursor calcium sulphate hemihydrate was prepared, e.g. particle size distribution.
  • the curing time of such a calcium sulphate mixture may be controlled by the presence of a retardant. It is preferred that the resulting calcium dehydrate paste may be ejected using a regular syringe equipped with a regular or small cannula.
  • a retardant is carboxymethylcellulose, notably the sodium salt thereof (Na-CMC).
  • the amount of such Na-CMC is usually about 0.1 to 5 wt%, such as 0.25%.
  • Such a calcium sulphate mixture may comprise a mixture of non-compressed and compressed calcium sulphate. Such mixture comprising a mixture of non-compressed and compressed calcium sulphate may have different physical properties and release rates / release profiles depending on the ratio between non-compressed and compressed calcium sulfate. Such ratio may vary from about 100:1 to about 1 : 100.
  • Such binary mixture can further be conventionally compressed in STING modulating molecules -loaded dense granules (or bodies).
  • the STING modulating molecules - loaded dense granules (or bodies) will have different physical properties and release rates / release profiles depending on how it is prepared, for example which pressure that was used in the densifying step. Suitable pressures are 1000 - 5000 bar for about 1-3 hours.
  • such STING modulating molecules -loaded dense granules are prepared by wetting calcium sulphate hemihydrate, with enough water to convert it to calcium sulphate dihydrate and simultaneously apply a pressure of about 4000 bar for about 1 hour.
  • a controlled-release pharmaceutical composition according to the present invention may comprise a mixture of non-compressed and compressed ceramic material, such as calcium sulphate.
  • the STING modulating molecules can be either agonists or antagonists, of which agonists are preferred.
  • STING agonists include naturally occurring and synthetic cyclic dinucleotides.
  • the term cyclic dinucleotide represents a class of cyclic molecules where two nucleotides are connected by two phosphodiester linkages, two phosphorothioate diester linkages or one phosphodiester and one phosphorothioate diester linkage.
  • the linkages can be (3’- 5’)-(3’-5’), (3’-5’)-(2’-5’), (2’-5’)-(3’-5’) or (2’-5’)-(2’-5’) and all are within the scope of the present invention.
  • Phosphorothioate linkages are inherently chiral and cyclic dinucleotides can therefore exist in in chiral or diastereomeric forms.
  • Such diastereomeric form of a phosphorothioate is preferably an optically pure diastereoisomer or optically pure form.
  • optically pure means an isomeric excess over other isomers greater than about 80%, preferably greater than about 90%, preferably greater than about 95%, more preferably greater than about 97%, even more preferably greater than about 99%, more preferably greater than about 99.5% or more, and most preferably up to 100%, wherein the remainder may be one or more of the other isomers.
  • Cyclic dinucleotides include, but are not limited to, c-di-adenosine monophosphate (AMP), c-di-guanosine monophosphate (GMP), c-di-inosine monophosphate (IMP), c- AMP- GMP, c- AMP-IMP, and c-GMP-IMP, and analogs thereof including, but not limited to, phosphorothioate analogues.
  • Bi and B 2 are purine bases independently selected from adenosine, guanine, or hypoxanthine;
  • Qi and Q 2 are independently selected from H, OH or F;
  • Yi and Y 2 are independently selected from O or S, or a pharmaceutically acceptable salt thereof.
  • cyclic dinucleotides that act as STING modulating molecules include:
  • STING modulating agents or molecules maybe small molecule analogs or derivatives of flavone acetic acid (FAA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and 10-(carboxymethyl)-9(10H)acridone.
  • FAA flavone acetic acid
  • DMXAA 5,6-dimethylxanthenone-4-acetic acid
  • 10-(carboxymethyl)-9(10H)acridone be small molecule analogs or derivatives of flavone acetic acid (FAA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and 10-(carboxymethyl)-9(10H)acridone.
  • the STING modulating molecules can also be dispiro diketopiperazine (DSDP) derivatives.
  • DSDP dispiro diketopiperazine
  • the STING modulating molecules can be immunomodulatory compounds that can be used in combination therapy methods.
  • a further aspect is to administer the pharmaceutical compositions of the present invention, i.e. containing a therapeutically, prophylactically, and/or diagnostically active STING modulating molecule, to a human or animal subject in need of such treatment.
  • Such treatments include, but is not limited to, hyperproliferative diseases such as cancer and including advanced cancer.
  • such a cancer is selected from (a) solid cancers including, but not limited to, sarcomas, breast cancer, prostate cancer, head and neck cancer, brain tumors, colorectal cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, melanoma, gastric cancers, renal cell carcinoma, endometrial cancer, sarcomas and hepatocellular carcinomas; (b) hematological cancers including, but not limited to, chronic myelogenous leukemia, acute myelogenous leukemia, cutaneous T-cell lymphoma, Hodgkin’s disease, anaplastic large-cell lymphoma and Burkitt’s lymphoma.
  • solid cancers including, but not limited to, sarcomas, breast cancer, prostate cancer, head and neck cancer, brain tumors, colorectal cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, melanoma, gastric cancers, renal cell carcinoma, endometrial cancer, s
  • compositions of the present invention may be injected into a tumor site, preferably intratumorally or adjacent to the tumor, (such as at a distance of 0.1 -10 mm), to a solid tumor.
  • the tumor may be a primary tumor or a metastasis.
  • the formulation is injected intratumorally where it solidifies to a solid local depot (comparable to a drug eluting implant) which over time dissolves and releases the active substance locally.
  • a solid local depot component that dissolves and releases the active substance locally.
  • the local solidification of the formulation facilitates a controlled local administration of the active substance.
  • the locally solidifying formulation forming a local drug depot may also be injected adjacent to a tumor or to a location characterized by the presence of cancer cells and cancerous tissues.
  • the injected formulation may be administered in different ways to the tumor or cancerous tissue, depending on the size, shape and distribution of the tumor or cancer tissue.
  • the injection may be focused to one solid depot to optimally focus the release to the interior of one tumor; or several depots of similar or different shapes may be injected to cover a larger area or treat several tumors; or the depot may be injected as strings or range of smaller depots to adapt to a tumor of undefined or irregular shape.
  • Any such injected formulation may consist of a mixture of a non-compressed and compressed ceramic material, such as calcium sulphate.
  • the present invention thus provides a method of treating a subject, such as a human being, afflicted with a tumor, comprising administering to a tumor site a hydratable and bioresorbable ceramic, preferably calcium sulphate, comprising a STING modulating molecule.
  • a subject such as a human being
  • a hydratable and bioresorbable ceramic preferably calcium sulphate
  • Such method of treating a subject may result in (a) reducing the volume of the tumor; (b) reducing the growth of the tumor; (c) reducing metastasis of the tumor; (d) increasing the survival of the subject; (e) increasing the progression free survival of the subject; and/or (f) increasing a T cell response to an antigen within the tumor.
  • One aspect of the present invention provides a method to reducing the volume of a tumor at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100 percent, by administering to a tumor site a hydratable and bioresorbable ceramic, preferably calcium sulphate, comprising a STING modulating molecule.
  • a hydratable and bioresorbable ceramic preferably calcium sulphate, comprising a STING modulating molecule.
  • Such reduction of volume usually occurs within 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 21 , 28, 35, 42, 49, 180, 365 or 1 -365 days or within about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , or 12 months.
  • compositions of the present invention are advantageous since they have a controlled-release profile and thus requires less frequent and/or less number of injections compared to compositions of the prior art. Each administration is costly, time consuming and painful to the receiving patient and the compositions of the present invention are thus likely to improve a patient’s compliance.
  • compositions of the present invention are further advantageous since they induce fewer adverse events compare to an immediate-release formulation.
  • Adverse events are most likely to occur at or near the maximum (or peak) serum concentration (C max ) of a drug.
  • compositions of the present invention are yet further advantageous since they combine a pharmacologically active STING modulating with a bioresorbable carrier that has been proven safe and tolerated in humans.
  • the compositions of the present invention comprise a hydratable and bioresorbable ceramic, preferably calcium sulphate.
  • One aspect of the present invention is a controlled-release composition comprising a non-densified and porous hydratable and bioresorbable ceramic.
  • One aspect of the present invention is a controlled-release composition
  • a controlled-release composition comprising highly densified and non-porous hydratable and bioresorbable ceramic, such as calcium sulphate.
  • One aspect of the present invention is a controlled-release composition
  • a controlled-release composition comprising a mixture of a non-densified and porous with a highly densified and non-porous hydratable and bioresorbable ceramic, such as calcium sulphate.
  • One aspect of the present invention is to provide a controlled-release composition (or depot) that releases the STING modulating molecules over a total period of at least about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 weeks, whereby the release rate of STING modulating molecules is approximately constant during the total time period either in vivo or when subjected to an in vitro dissolution test according to established using USP or European Pharmacopeia methods, or similar laboratory in vitro release methods, such as USP apparatus 7 (37 degrees physiological saline, 5 dips per minute) or similar; or e.g. USP apparatus 4 (37 degrees physiological saline, large cell, 19 ml medium, minimal flow) or similar.
  • a controlled-release formulation provides a pharmacological acceptable and useful balance between safety and efficacy.
  • One aspect of the present invention is to provide a controlled-release composition (or depot) that releases the STING modulating molecules over a total period of at least about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12 or 13 weeks, whereby a release of 20-80%, such as 30-60% or 40-50% of the total amount of STING modulating molecules in the composition is released within the first half of the time period, or during the first third of the time period either in vivo or when subjected to an in vitro dissolution test according to established using USP or European Pharmacopeia methods, or similar laboratory in vitro release methods, such as USP apparatus 7 (37 degrees physiological saline, 5 dips per minute) or similar; or e.g. USP apparatus 4 (37 degrees physiological saline, large cell, 19 ml medium, minimal flow) or similar.
  • a controlled-release formulation provides a pharmacological acceptable and useful balance between safety and efficacy.
  • One aspect of the present invention is to provide a controlled-release composition with a release profile over an extended period of time defined by a faster initial release during the first half of the total treatment time, or during the first third of the total treatment time, followed by a slower release for the remaining duration of the treatment, when tested according to established USP or European Pharmacopeia drug release methods, such as USP apparatus 7 (37 degrees physiological saline, 5 dips per minute) or similar; or e.g. USP apparatus 4 (37 degrees physiological saline, large cell, 19 ml medium, minimal flow) or similar.
  • USP apparatus 7 37 degrees physiological saline, 5 dips per minute
  • USP apparatus 4 37 degrees physiological saline, large cell, 19 ml medium, minimal flow
  • One aspect of the present invention is to provide a controlled-release composition with a release profile over an extended period of time defined by a slower initial release that may or may not include an initial time period with no release at all during the first half of the total treatment time, such as during the first third of the total treatment time, followed by a faster release for the remaining duration of the treatment, when tested according to established USP or European Pharmacopeia drug release methods, such as USP apparatus 7 (37 degrees physiological saline, 5 dips per minute) or similar; or e.g. USP apparatus 4 (37 degrees physiological saline, large cell, 19 ml medium, minimal flow) or similar.
  • USP apparatus 7 37 degrees physiological saline, 5 dips per minute
  • USP apparatus 4 37 degrees physiological saline, large cell, 19 ml medium, minimal flow
  • One aspect of the present invention is to provide a controlled-release composition (or depot) that releases the STING modulating molecules over a total period of at least about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12 or 13 weeks, whereby two or more different release rates are present either in vivo or when subjected to an in vitro dissolution test according to established using USP or European Pharmacopeia methods, or similar laboratory in vitro release methods, such as USP apparatus 7 (37 degrees
  • a controlled-release formulation provides a pharmacological acceptable and useful balance between safety and efficacy.
  • the present invention thus delivers a pharmaceutical formulation with a slow release capability and a release equilibrium well beyond 14 hours.
  • Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • suitable doses of the pharmaceutically active agent range from about 0.01 to 100 pg active compound per kilogram body weight.
  • pharmaceutically active agent vary from 0.7 to 7000 pg.
  • STING modulating molecules contemplated for use in the invention are given in Table 1.
  • ML-RR-S2 CDA is a potent STING-activating cyclic di-adenosine (CDA or c- diAMP) nucleotide ligand that contains non-canonical 2',5'-phosphodiester bond and doubly substituted thiophosphate (S2) for optimal phosphodiesterase-resistance and thereby enhanced cellular potency.
  • CDA cyclic di-adenosine
  • S2 doubly substituted thiophosphate
  • ML-RR-S2 CDA effectively induces IRF3, NF-kB, and STAT6 transcription activities in a STING-dependent manner in both murine and human cell cultures (5-100 pM) as well as displays profound anti-tumor efficacy in vivo (100% growth inhibition of established B16.F10, 4T-1 or CT26 tumor with 3X 50 pg/mouse/96 hr intratumoral injections) with lasting immune-mediated tumor rejection.
  • ML RR-S2 CDA also known as ADU-S100 and MIW815, is a cyclic dinucleotide with the following structure:
  • ML RR-S2 CDA or ADU-S100 is an inducer of STING (stimulator of interferon genes).
  • ADU-S100 has enhanced binding affinity to STING and activate all known human STING alleles.
  • the calcium sulfate formulation loaded with STING modulating molecules can be used alone or in combination with systemic immunotherapies. More specifically be used with checkpoint inhibitors including anti-CTLA4, anti-PD-1 or anti-PD-L1 antibodies (e.g. Ipilimumab, Tremelimumab, Pembrolizumab, Nivolumab (PD1 ), Atezolizumab
  • checkpoint inhibitors including anti-CTLA4, anti-PD-1 or anti-PD-L1 antibodies (e.g. Ipilimumab, Tremelimumab, Pembrolizumab, Nivolumab (PD1 ), Atezolizumab
  • Such combination therapy or combined administration may be in a fixed combination product or using concomitant and/or sequential administration.
  • the advantages of immunotherapy using calcium sulfate formulation loaded with STING modulating molecules include decreased systemic side-effects, increased efficacy through direct activation of the innate immune system in the tumor
  • controlled-release as used herein relates to a mechanism that delivers an active pharmaceutical ingredient (API) with a delay after its administration or for a prolonged period after its administration or with a release profile that is substantially different than an immediate release profile.
  • API active pharmaceutical ingredient
  • immunotherapeutic agent as used herein relates to a medicament capable of inducing, enhancing, or suppressing an immune response.
  • immunotherapy as used herein relates to the treatment of a disease by inducing, enhancing, or suppressing an immune response.
  • Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppressive immunotherapies
  • STING modulating molecule as used herein relates to a molecule that can activate or inhibit the stimulator of interferon genes (STING) protein or STING pathway.
  • small molecule as used herein relates to a low molecular weight ( ⁇ 900 daltons) organic compound that may regulate a biological process.
  • the purpose of the example is a preliminary evaluation of the possibilities to
  • STING agonists are potent mediators of immune activation and anti-tumor effects.
  • STING agonists are potent mediators of immune activation and anti-tumor effects.
  • the purpose of the experiment was to assess a potential local immunotherapy as a means to reduce toxicity in humans in a future locally injectable drug product.
  • the STING agonist (ML RR-S2 CDA ammonium salt) is dissolved in 2-propanol in the ratio of 1 :450. This solution is then mixed under magnetic stirring at 35°C during 15 minutes making a clear solution. Micronized calcium sulfate hemihydrate is added to the solution to an amount that generate a final dry powder containing 0.6 wt.% STING agonist. The suspension is evaporated for 20 hours to form a“cake-like” dry powder adhered to the inside of the evaporation glass vessel. The cake is broken and sieved through a 200 pm mesh sieve to achieve a free-flowing powder.
  • the powder Prior to administration the powder is mixed with an aqueous diluent in the weight ratio of 1 :1 , where the diluent is 0.25 wt.% sodium carboxymethylcellulose (Na-CMC) in purified water.
  • the diluent is mixed thoroughly by docking the male Luer-Lok syringe containing diluent with the female Luer-Lok powder syringe and then pushing the pistons back and forth several times to create a homogeneous suspension.
  • the powder syringe is then changed to a suitable injection needle and after priming, the drug product (reconstituted suspension) is prepared to be used for injection.
  • the depot formulation is injected locally with a suitable volume into the tumor, where the formulation solidifies within approximately 10-20 minutes.
  • the purpose of the experiment was to examine the release of a STING agonist into a solution from the depot formulation.
  • the formed tablet was placed in a solution of PBS at 37°C.
  • the concentration of the STING agonist was measured initially and after 7 days.
  • the relative release was measured to approximately 60% after 7 days.
  • Example 3 The purpose of Example 3 is to evaluate the antitumor effect of a STING agonist formulated in calcium sulfate prepared as in Example 1. The results are shown in Figure 1 and 2.
  • a preparation of 5x10 5 B16F10 cells in PBS was injected subcutaneously into the flank of female B6D2F1 mice in a total injection volume of 100 pi. Animals bearing tumors of preferably >100 mm 3 were assigned to treatment groups and therapy as conducted as outlined in Table 3.
  • a dry powder containing ML-RR-S2 CDA finely distributed in Ca 2 S0 4 was mixed with a 0.25% Na-CMC aqueous solution at proportions of 1 ml of solution to 1 g of powder, forming a viscous but injectable paste.
  • 50 pL of Nanozolid was injected intratumorally using a 21 G syringe on the day of randomization.
  • Tumor volumes and body weights were determined three times a week. For animal welfare regulations (fast growth of syngeneic models), animals that reached a tumor volume of 1500 mm 3 were terminated.
  • Figure 1 shows the tumor growth of syngeneic tumors following intratumoral adminsitration of a controlled release formulation of a STING agonist according to Example 3.
  • calcium sulfate formulated STING agonist significantly reduced the tumor growth when given as a single intratumoral injection. This resulted in an increased survival ( Figure 2), Figure 2 showing survival of animals treated in Example 3.
  • Example 4
  • Example 4 The purpose of Example 4 is to evaluate the antitumor effect of different doses of a STING agonist formulated in calcium sulfate prepared as in Example 1. The results are shown in Figure 3 and 4.
  • mice were inoculated with 5 x 10 5 B16-F10 cells, in a volume of 100 pl_, via subcutaneous (s.c.) injection in the rear flank. When the majority of the tumors had reached a volume of 100 mI_, 25 animals were stratified into five
  • a dry powder containing ML-RR-S2 CDA finely distributed in Ca 2 S0 4 was mixed with a 0.25% Na-CMC aqueous solution at proportions of 1 ml of solution to 1 g of powder, forming a viscous but injectable paste.
  • 50 pl_ of Nanozolid was injected intratumorally (it) using a 21 G syringe on the day of randomization.
  • the number of positive cells in tumors was judged as; negative (0), few positive cells (1 +), few to moderate numbers (1 -2+), moderate numbers of positive cells (2+), moderate to high numbers (2-3+) or high numbers of positive cells (3+).
  • mice demonstrated a general increase in body weight from Day -8 to Day 10. Treatment with test item had no effect on body weight. Treatment with test item had a significant effect on tumor volume (p ⁇ 0.0001 ) ( Figure 3). Whereas animals in Group 1 (NZ-Vehicle) demonstrated a significant increase in tumor size from the first day on which tumors were measurable (Day -2) to the final day of the study, this was not evident in the remaining groups. Specifically, on the final day of the study, tumor volumes were significantly smaller in all treatment groups, as compared to the NZ- Vehicle group (Group 1 ). The effect of treatment was further corroborated by tumor weight, where tumors in Groups 2, 3 and 5 were significantly smaller than tumors in Group 1 (NZ-Vehicle).
  • Figure 3 shows the tumor growth of individual syngeneic tumors following intratumoral adminsitration of a a STING agonist according to Example 4 for the respective groups 1-5.
  • calcium sulfate formulated STING agonist significantly reduced the tumor growth when given as a single intratumoral injection.
  • Figure 4 shows the terminal tumor weight, as recorded following excision on the final day of the study in Example 4.
  • animals treated with a single intratumoral injection of calcium sulfate formulated STING agonist had tumors of significantly reduced size compared to untreated animals.
  • the purpose of the example was a preliminary evaluation of the possibilities to long- term store a powder consisting of an incorporated STING modulating molecule in a calcium sulfate matrix at room temperature, and to be able to release the STING modulating molecules both in vitro and in vivo with the intended release profile and maintained bio-functionality, also after storage.
  • the concentration of 0.46 wt.% in the powder was chosen in order to be able to inject a dose of 150 pg STING modulating molecule per 50 pi reconstituted homogeneous suspension.
  • the STING agonist (ML RR-S2 CDA ammonium salt) was dissolved in 2-propanol in the ratio of 1 : 1400. This solution was then mixed under magnetic stirring at 35°C for 40 minutes making a clear solution. Micronized calcium sulfate hemihydrate was added to the solution to an amount that generate a final dry powder containing 0.46 wt.% STING agonist. The suspension was evaporated for 2.5 hours to form a“cake-like” dry powder adhered to the inside of the evaporation glass vessel. The cake was broken and sieved through a 125 pm mesh sieve to achieve a free-flowing powder. The powder was then filled into plastic female Luer-Lok syringes, where the piston is positioned to have a minimal dead space without compressing the powder, and then closed with a plastic Luer-Lok stopper.
  • the powder Prior to administration the powder was mixed with an aqueous diluent in the weight ratio of 1 :1 , where the diluent was 0.25 wt.% sodium carboxymethylcellulose (Na-CMC) in purified water.
  • the diluent was mixed thoroughly by docking the male Luer-Lok syringe containing diluent with the female Luer-Lok powder syringe and then pushing the pistons back and forth several times to create a homogeneous suspension.
  • the powder syringe was then changed to a suitable injection needle and after priming, the reconstituted suspension was prepared to be used for injection.
  • the depot formulation was injected locally with a suitable volume into the tumor, where the formulation solidified within approximately 10-20 minutes.
  • Example 5 The in vivo and in vitro characteristics were essentially similar as for Example 1 above. Assay was measured after six months of storage. In conclusion, the analyses of Example 5 showed that the powder can be stored as a dry powder for at least six months at room temperature in plastic containers with maintained functionality.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouvelles compositions pharmaceutiques comprenant une céramique d'hydratation non densifiée et poreuse ou hautement densifiée et non poreuse, et au moins partiellement hydratée, telle que du sulfate de calcium, pour la libération contrôlée d'une ou de plusieurs molécules modulant STING, de préférence des agonistes de STING, à des fins thérapeutiques, prophylactiques et/ou diagnostiques.
PCT/EP2019/056006 2018-03-09 2019-03-11 Compositions biorésorbables à libération contrôlée comprenant des molécules modulant sting WO2019170912A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2018/055910 2018-03-09
EP2018055910 2018-03-09

Publications (1)

Publication Number Publication Date
WO2019170912A1 true WO2019170912A1 (fr) 2019-09-12

Family

ID=65635734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/056006 WO2019170912A1 (fr) 2018-03-09 2019-03-11 Compositions biorésorbables à libération contrôlée comprenant des molécules modulant sting

Country Status (1)

Country Link
WO (1) WO2019170912A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021206158A1 (fr) 2020-04-10 2021-10-14 小野薬品工業株式会社 Méthode de cancérothérapie
WO2021216698A1 (fr) * 2020-04-21 2021-10-28 Duke University Compositions et procédés pour le traitement de la douleur
EP4114417A4 (fr) * 2020-03-06 2024-08-14 Od Therapeutics Ltd Agents thérapeutiques et leur conjugués

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2005039537A1 (fr) 2003-10-22 2005-05-06 Lidds Ab Composition comprenant des ceramiques d'hydratation biodegradables pour une administration de medicaments commandee
WO2007104549A2 (fr) 2006-03-14 2007-09-20 Lidds Ab Composition biorésorbable à libération contrôlée
WO2008118096A1 (fr) * 2007-03-28 2008-10-02 Doxa Ab Support pour l'administration de médicaments
WO2016096577A1 (fr) * 2014-12-16 2016-06-23 Invivogen Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer
WO2017186711A1 (fr) 2016-04-25 2017-11-02 Invivogen Nouveaux complexes de composés immunostimulateurs, et leurs utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US20030170307A1 (en) 1997-09-22 2003-09-11 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6630486B1 (en) 1997-09-22 2003-10-07 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2005039537A1 (fr) 2003-10-22 2005-05-06 Lidds Ab Composition comprenant des ceramiques d'hydratation biodegradables pour une administration de medicaments commandee
WO2007104549A2 (fr) 2006-03-14 2007-09-20 Lidds Ab Composition biorésorbable à libération contrôlée
WO2008118096A1 (fr) * 2007-03-28 2008-10-02 Doxa Ab Support pour l'administration de médicaments
WO2016096577A1 (fr) * 2014-12-16 2016-06-23 Invivogen Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer
WO2017186711A1 (fr) 2016-04-25 2017-11-02 Invivogen Nouveaux complexes de composés immunostimulateurs, et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JUNKINS ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 270, 2018, pages 1 - 13
KOSHY ET AL., ADV. BIOSYS., vol. 1, 2017, pages 1600013
LEAH ET AL., BIOMATERIALS, vol. 163, 2018, pages 67e75
NAKAMURA ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 216, 2015, pages 149 - 157
WILSON ET AL., NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, vol. 14, 2018, pages 237 - 246

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114417A4 (fr) * 2020-03-06 2024-08-14 Od Therapeutics Ltd Agents thérapeutiques et leur conjugués
WO2021206158A1 (fr) 2020-04-10 2021-10-14 小野薬品工業株式会社 Méthode de cancérothérapie
WO2021216698A1 (fr) * 2020-04-21 2021-10-28 Duke University Compositions et procédés pour le traitement de la douleur
EP4138852A1 (fr) * 2020-04-21 2023-03-01 Duke University Compositions et procédés pour le traitement de la douleur
EP4138852A4 (fr) * 2020-04-21 2024-05-15 Duke University Compositions et procédés pour le traitement de la douleur

Similar Documents

Publication Publication Date Title
Yang et al. Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy
JP2750138B2 (ja) 細胞毒性薬との組合せにおける血管収縮性物質
JP5415769B2 (ja) 経鼻投与用製剤
WO2019170912A1 (fr) Compositions biorésorbables à libération contrôlée comprenant des molécules modulant sting
TW200529842A (en) Excipients in drug delivery vehicles
Cui et al. Hydrogel-by-design: smart delivery system for cancer immunotherapy
JP2015229675A (ja) 膵臓癌を治療するための医薬製剤
JP2001502331A (ja) 脳腫瘍に対するサイトカインで増強した免疫療法
EP1872798B1 (fr) Agent anti-tumeur absorbable par l intestin
US20160346398A1 (en) Cross-linked hyaluronic acid for drug delivery and pharmaceutical preparation using same
Shao et al. KERS‐Inspired Nanostructured Mineral Coatings Boost IFN‐γ mRNA Therapeutic Index for Antitumor Immunotherapy
CN102316855A (zh) 基于需求并可逆的通过外部信号进行的药物释放
CN101181230A (zh) 一种治疗实体肿瘤的雌二醇氮芥缓释植入剂
CN101185629A (zh) 一种治疗实体肿瘤的地西他滨缓释剂
US20050266076A1 (en) Resorbable delivery systems for the treatment of cancer
IL277802B1 (en) Sustained-release letrozole injection
CN101637444B (zh) 含吉西他滨的抗癌药物缓释注射剂
CN101219101A (zh) 一种治疗实体肿瘤的氟达拉滨缓释植入剂
CN100500215C (zh) 含氨甲喋呤及其增效剂的缓释注射剂
CN101427994B (zh) 一种含吉西他滨的抗癌药物缓释注射剂
EP2601974A1 (fr) Préparation pharmaceutique pour contrôler la libération d'un médicament soluble dans l'eau
CN101204369A (zh) 一种治疗实体肿瘤的索非拉尼缓释植入剂
CN101181232A (zh) 一种治疗实体肿瘤的马赛替尼缓释植入剂
JP2008106024A (ja) たんぱく性薬物含有徐放性微粒子組成物およびその製造方法
WO2024206077A2 (fr) Régimes de dosage et polythérapies utilisant l'archivexine pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19708573

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19708573

Country of ref document: EP

Kind code of ref document: A1